Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V116 versus PCV15 followed by PPSV23 in at-risk pneumococcal vaccine-naive adults aged 18 to 64 years
2022-502791-22-01Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with solicited injection-site adverse events, Percentage of participants with solicited systemic adverse events and 2 more. Started Apr 2023; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2022-502791-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502791-22-01.